GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stimcell Energetics Inc (OTCPK:STME) » Definitions » Net Current Asset Value

STME (Stimcell Energetics) Net Current Asset Value : $-0.05 (As of Feb. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Stimcell Energetics Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Stimcell Energetics's net current asset value per share for the quarter that ended in Feb. 2025 was $-0.05.

The historical rank and industry rank for Stimcell Energetics's Net Current Asset Value or its related term are showing as below:

STME's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 4.755
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Stimcell Energetics Net Current Asset Value Historical Data

The historical data trend for Stimcell Energetics's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stimcell Energetics Net Current Asset Value Chart

Stimcell Energetics Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 May23 May24
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.41 -0.38 -0.48 -0.57 -0.04

Stimcell Energetics Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.04 -0.05 -0.05 -0.05

Competitive Comparison of Stimcell Energetics's Net Current Asset Value

For the Medical Devices subindustry, Stimcell Energetics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stimcell Energetics's Price-to-Net-Current-Asset-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Stimcell Energetics's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Stimcell Energetics's Price-to-Net-Current-Asset-Value falls into.


;
;

Stimcell Energetics Net Current Asset Value Calculation

Stimcell Energetics's Net Current Asset Value (NCAV) per share for the fiscal year that ended in May. 2024 is calculated as

Net Current Asset Value Per Share(A: May. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(0.046-0.873-0-0)/19.816
=-0.04

Stimcell Energetics's Net Current Asset Value (NCAV) per share for the quarter that ended in Feb. 2025 is calculated as

Net Current Asset Value Per Share(Q: Feb. 2025 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(0.017-1.087-0-0)/19.816
=-0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stimcell Energetics  (OTCPK:STME) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Stimcell Energetics Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Stimcell Energetics's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Stimcell Energetics Business Description

Traded in Other Exchanges
N/A
Address
1130 Pender Street, West, Suite 820, Vancouver, BC, CAN, V6E 4A4
Stimcell Energetics Inc is a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that enhance cellular function, promote general wellness and alleviate health complications including, but not limited to: aging, diabetes, high blood pressure, neuropathy and kidney function. The Company's main focus is on continued research and development of its eBalance Technology and its eBalance Home System.
Executives
Richard Jeffs 10 percent owner FLAT 7, 6 ENNISMORE GARDENS, LONDON X0 SW7 1NL
Dwayne Yaretz director, officer: Chief Executive Officer SUITE 1050 WEST PENDER STREET SUITE 2250, VANCOUVER A1 V6E 3S7
Bradley S Hargreaves 10 percent owner 904-1616 BAYSHORE DR, VANCOUVER A1 V6G3L1
Frank Mcenulty director, officer: CEO, CFO, Treas., Sec 4182 N. VIKING WAY, SUITE 216, LONG BEACH CA 90808-1475
Joao Dacosta director, officer: COO #810 - 789 WEST PENDER STREET, VANCOUVER A1 V6C 1H2
George Adams director 7535 CONSERVATION ROAD, GUELPH A6 N1H6J1
Terrance George Owen director, officer: CEO 635 FOURTH LINE (UNIT 1), OAKVILLE A6 L6L 5BO
John David Sanderson officer: Chief Medical Officer 9 ISLANDVIEW, IRVINE CA 92604
Yanika S Silina officer: CFO, Treasurer and Secretary 789 WEST PENDER STREET, UNIT 810, VANCOUVER A1 V6C 1H2
Jean M Arnett 10 percent owner 121 - 3989 HENNING DRIVE, BURNABY A1 V5C 6P8
Ean Kremer director, officer: Chief Technology Officer C/O PLANDEL RESOURCES, INC., 4575 DEAN MARTIN DRIVE, STE. 2206, LAS VEGAS NV 89103